Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif (R) new formulation) in a phase IIIb study in patients with relapsing multiple sclerosis: 96-week results
2008
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
45
Citations
NaN
KQI